Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...
Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...
We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...
GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.
A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...